Clinical trials: Drug Drug Interaction Study
Drug Interaction Potentiation
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg
Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 50mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.
- Trial name
- NCT02485028
- Testing
- Dapoxetine 30mg tablet, Mirodenafil 50mg tablet
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
HIV
Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy
This will be a cross-sectional population-based study carried out in the region of Madrid (6,468,322 inhabitants according to current census) to quantify the number of Co-meds in HIV-infected individuals on ART in the region of…
- Trial name
- PODIUM (NCT03123575)
- Volunteers
- 1,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
cMET-dysregulated Advanced Solid Tumors
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
- Trial name
- NCT02626234
- Testing
- INC280, digoxin, rosuvastatin
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Clinical Trial, Phase I
Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan
This is a study in postmenopausal women to investigate the Drug-drug interaction (DDI) between itraconazole(ITZ) and orally administered vilaprisan; absolute bioavailability using intravenous microtracer dose of [14C]vilaprisan.
- Trial name
- NCT02456129
- Testing
- Vilaprisan (BAY1002670), [14C] Vilaprisan, Itraconazole(ITZ)
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Interaction Drug Food
Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride
Sixty-eight healthy subjects were divided into three sequences: A, B and C. The effects of CYP2C19 inhibitor fluconazole and inducer rifampicin on ET-26-HCl injection were evaluated, and the effects of ET-26-HCl injection on…
- Trial name
- NCT06822166
- Testing
- rifampicin, Fluconazole, Omeprazole
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ahon Pharmaceutical Co., Ltd.
Transgender Health, Gender Dysphoria
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy.
- Conditions
- Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
- Trial name
- IDENTIFY (NCT04283656)
- Testing
- Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Healthy Adult Participants
A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)
The purpose of the study is to learn how itraconazole changes how the body processes the study medicine called PF-07248144. The study will also look at the safety, tolerability, and how PF-07248144 is changed and removed from the…
- Trial name
- NCT07335419
- Testing
- PF-07248144, Itraconazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
Study of Lemborexant-Alcohol Interaction in Healthy Subjects
This study will be conducted to evaluate the effects on cognitive performance (Power of Attention domain) and postural stability of lemborexant in combination with alcohol versus lemborexant alone and versus alcohol alone in…
- Trial name
- NCT03483636
- Testing
- Lemborexant, Alcohol
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Nausea and Vomiting, Chemotherapy-Induced
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
The purpose of the study is to evaluate the effect of the study drug (GW679769) on a commonly used chemotherapy drug (docetaxel) which will be given I.V.
- Trial name
- NCT00440128
- Testing
- Docetaxel, Casopitant/Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Insomnia
A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
Primary Objective : To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects; Secondary Objective: To evaluate the safety of ticagrelor tablets in combination with…
- Trial name
- NCT06671470
- Testing
- YZJ-1139 tablets, Ticagrelor Tablets
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Drug Interaction Potentiation
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin
This is a single-center, randomized, 2-period, 2-sequence, cross-over study.
- Trial name
- NCT01146483
- Testing
- Rosuvastatin, Pantoprazole
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Drug-drug Interaction
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
The enzyme responsible for the conversion of elafibranor into its active metabolite, GFT1007, has not been formally identified, but it is believed to have similar characteristics to an α,β-ketoalkene reductase previously…
- Trial name
- NCT03985969
- Testing
- elafibranor, CHRONO-INDOCID
- Where
- France
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Genfit
Drug-Interactions
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
- Trial name
- NCT04764851
- Testing
- ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Dyslipidemia
Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers
This study is a randomized, open-label, single arm, multi-dose, crossover study to evaluate drug-drug interaction and safety after co-administration of D352 and D794 in healthy adult volunteers.
- Trial name
- NCT06758661
- Testing
- D352, D794
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
HIV Infections
The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex
To test the safety and tolerance of three different doses of recombinant human interleukin 2 (aldesleukin; IL-2), when it is given for five consecutive days to patients with AIDS or AIDS related complex (ARC), who have also…
- Trial name
- NCT00000986
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
- Trial name
- NCT06250205
- Testing
- Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NewAmsterdam Pharma
Healthy
Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women
This study will assess if itraconazole will affect the blood levels of Duavee when they are given together. This study will also assess if a subject's body size affects the blood levels of Duavee.
- Trial name
- CE/BZA (NCT02100553)
- Testing
- CE/BZA, Itraconazole
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dermatitis, Atopic
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
A Phase 1, Open Label, Parallel-Cohort, Randomized, Fixed Sequence Study To Evaluate The Pharmacokinetic Drug Drug Interaction Between PF-04965842 and Fkuvoxamine (cohort 1) or Fluconazole (Cohort 2) in healthy subjects.
- Trial name
- NCT03634345
- Testing
- Period 1 - Day 1: PF-04965842 administered, Period 2: Cohort 1: Fluvoxamine & PF-04965842, Period 2: Cohort 2: Fluconazole & PF-04965842
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cystic Fibrosis
A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
The purpose of this study is to examine the drug-drug interaction effects of ciprofloxacin, itraconazole, and rifampin on the pharmacokinetics of lumacaftor in combination with ivacaftor as well as to evaluate the potential…
- Trial name
- NCT01768663
- Testing
- Lumacaftor, Ivacaftor, Ciprofloxacin
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Infection, Human Immunodeficiency Virus
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
In this study, approximately 16 subjects will receive raltegravir 400mg twice daily for 5 days (Treatment A) followed by a washout period. In Period 2, subjects will receive GSK2248761 200mg once daily for 5 days (Treatment B).
- Trial name
- NCT01101893
- Testing
- Raltegravir, GSK2248761, GSK2248761 + Raltegravir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.